Talimogene Laherparepvec Plus Ipilimumab Promising for Advanced Melanoma

Share this content:
Talimogene laherparepvec plus ipilimumab improves the overall response rate over ipilimumab alone among patients with unresected, advanced melanoma.
Talimogene laherparepvec plus ipilimumab improves the overall response rate over ipilimumab alone among patients with unresected, advanced melanoma.
The following article features coverage from the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. Click here to read more of Cancer Therapy Advisor's conference coverage.

Talimogene laherparepvec plus ipilimumab improves the overall response rate (ORR) over ipilimumab alone among patients with unresected, advanced melanoma, according to a study presented at the 2017 American Society of Clinical Oncology (ASCO) meeting in Chicago, Illinois.1

Talimogene laherparepvec, an engineered oncolytic virus, is designed to replicate within tumors and to stimulate anti-tumor activity through granulocyte-macrophage colony-stimulating factor (GM-CSF) production.

For this phase 2, randomized trial (ClinicalTrials.gov Identifier: NCT01740297), researchers evaluated whether combining talimogene laherparepvec with ipilimumab, a CTLA-4 inhibitor, would improve outcomes among patients with melanoma over ipilimumab alone.

Of 198 included patients, 98 were assigned to the experimental arm (talimogene laherparepvec plus ipilimumab) and 100 were assigned to the control arm (ipilimumab only). Characteristics were similar between the 2 groups.

ORR, the primary endpoint, was 38.8% in the experimental arm and 18% for the control, including 13 complete responses in the former and 7 in the latter.

At the time the study was presented, 89% and 83% of responders in the experimental and control arms, respectively, remained in response.

Twenty-eight percent of patients in the experimental arm had grade 3 or worse treatment-related adverse events (AEs); this was true of 18% of patients in the control arm.

RELATED: Dabrafenib Plus Trametinib Promising in Melanoma

The authors concluded that the “study met the [primary] endpoint. ORR was significantly higher for [talimogene laherparepvec plus ipilimumab] vs [ipilimumab]; responses were not limited to injected lesions. Toxicity of [the] combination was tolerable with no unexpected AEs.”

Read more of Cancer Therapy Advisor's coverage of the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting by visiting the conference page.

Reference

  1. Chesney JA, Puzanov I, Ross MI, et al. Primary results from a randomized (1:1), open-label phase II study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected stage IIIB- IV melanoma. J Clin Oncol. 2017;35(suppl; abstr 9509).

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters